Overview of current adipose-derived stem cell (ADSCs) processing involved in therapeutic advancements: flow chart and regulation updates before and after COVID-19

Table 1 Point of care devices for bed side separation of SVF

Medical devise	Manufacturer	Closed/semi-closed	Separation method	Proceeded fat quantity (g)	Process duration (min)	Cell yield/g of fat Device/control (D/C)	Cell viability D/C or D	References
Celution R 800/CRS StemSource 900/MB	Cytori Therapeutics, Inc	Closed	Enzymatic	300 g	90	2.41 × 10⁶/NP	NP	[57, 58]
GID SVF-1, SVF-2	GID Group, Inc	Closed	Enzymatic	300 g	90	0.425 × 10⁶ ± 0.047 × 10⁶/0.795 × 10⁶ ± 0.228 × 10⁶	50–84%	[56, 57, 64,65,66,67]
Icellator®	Tissue Genesis, Inc.	Closed	Enzymatic	60	80	0.25–2.0 × 10⁶	64.5 ± 11.4	[57, 68, 69]
Puregraft™	Eurosilicone	Semi-closed	Mechanical	250	100	0.25 × 10⁶ ± 0,07 × 10⁶/0.79 × 10⁶ ± 0.228 × 10⁶	77%	[57]
Stem.pra®	Proteal	Closed	Mechanical	200	110	0.535 × 10⁶ ± 0.209 × 10⁶/0.795 × 10⁶ ± 0.228 × 10⁶	69%	[57]
Cha-Station™	PNC International Co., Ltd.	Semi-closed	Mechanical Enzymatic	200	90	0.05 × 10⁶	NA	[57, 70]
Sepax®	Biosafe Grop SA	Semi-closed	Mechanical	300	90–120	2.6 ± 1.2 × 10⁵/ML	NA	[55, 57]
UNISTATION™	NeoGenesis	Closed	Not provided	NP	NP	1.1 × 10⁵ ± 1.1 × 10⁵/2.0 × 10⁵ ± 1.7 × 10⁵	NA	[71]
Lipokit MaxStem	Medi-Khan’s	Semi-closed	Enzymatic	NP	88–120	0.35 × 10⁶	50–84	[56, 70]

Processing with the different devices is reported regarding the closed or semi-closed systems and their efficiency to separate SVF in terms of fat quantity, cell yield and viability, and duration. These devices provide all-in-one single-use kit for the SVF separation and might also contain their GMP-grade proteolytic enzymes. NP not provided and, NA not applicable

ISSN: 1757-6512